SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER

SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗

• 批准号: 8351886
• 负责人: PETER PUSHKO
• 金额: $ 148.31万
• 依托单位: MEDIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-29 至 2013-09-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8351886
• 关键词: Animal Model; Antibody Formation; Antigens; Biological Assay; CD8B1 gene; Cancer Control; Chemistry; Collaborations; Contracts; Data; Dendritic Cells; Development; Dose; Engineering; Evaluation; Genes; Goals; Human; Immunotherapy; Malignant neoplasm of prostate; Maryland; Methods; Mus; Phase; Preparation; Procedures; Process; Production; Prostate Cancer Vaccine; Prostate-Specific Antigen; Public Health; Quality Control; Regimen; Research; Route; Safety; Serum; Small Business Innovation Research Grant; Structure of base of prostate; Synthetic Vaccines; T-Lymphocyte; Transgenic Mice; United States Food and Drug Administration; Universities; Vaccinated; Vaccination; Vaccine Antigen; Vaccine Production; Vaccines; Variant; Virus-like particle; assay development; cancer immunotherapy; design; expression vector; follow-up; immunogenicity; improved; in vivo; meetings; novel; novel therapeutics; novel vaccines; protective effect; protective efficacy; research study; scale up; therapeutic vaccine; tumor; vaccine candidate; vaccine efficacy; vector

This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novel ¿vector VLP¿ (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.

该二期SBIR合同用于先进的疫苗效力研究，其中涉及接种PSA+转基因小鼠的TRAMP肿瘤攻击。为提高免疫原性而设计的PSA变体将使用新型载体VLP（vVLP_ vaccine platform）在PSA+小鼠中递送和表达。后者代表非复制型病毒样颗粒，其被配置为包裹表达载体以用于体内递送和表达工程化PSA基因。